Company Description
Impact Biomedical Inc. is a subsidiary of DSS, Inc (“DSS”: NYSE).
IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.
Our activities range from the discovery of technologies and leveraging those technologies to create and commercialize product candidates.
Currently, our operations are conducted, and our assets are owned primarily through our principal subsidiaries: (i) Global BioLife, (ii) Impact BioLife Science, Global BioMedical and (iii) Sweet Sense, Inc. By leveraging technology and new science with strategic partnerships, we provide advances in drug discovery for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases.
Other exciting technologies include natural compositions for over-the-counter upper respiratory, anti-viral and other conditions, functional fragrance formulations for use in lotions, insect repellents, and other consumer products and a unique alternative sugar composition, with potential to impact calorie intake and glycemic index.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Frank D. Heuszel |
Contact Details
Address: 1400 Broadfield Blvd., Suite 130 Houston, TX 77084 United States | |
| Phone | (585) 325-3610 |
| Website | impactbiomedinc.com |
Stock Details
| Ticker Symbol | IBO |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001834105 |
| Employer ID | 85-3926944 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Heng Fai Ambrose Chan | Chairman of the Board |
| Frank D. Heuszel | Chief Executive Officer and Director |
| Mark Suseck | Chief Operating Officer |
| Todd D. Macko | Chief Financial Officer |
| Dr. Elise Brownell | Director |
| Melissa Sims | Director |
| David Keene | Director |
| Christian Zimmerman | Director |
| Castel Hibbert | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 7, 2024 | 8-K | Current Report |
| May 10, 2024 | 10-Q | Quarterly Report |
| Feb 28, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 20, 2024 | 10-K | Annual Report |
| Jan 22, 2024 | 8-K | Current Report |
| Nov 21, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 6, 2023 | 8-K | Current Report |
| Nov 1, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |